Belsomra (Suvorexant) Geriatric Dosing: Safe Use in Adults 65 and Older

Why Suvorexant Is Different from Older Sleep Medications in Geriatric Patients

Suvorexant works by blocking orexin receptors (OX1R and OX2R), which promote wakefulness. This mechanism is distinct from benzodiazepines and Z-drugs (zolpidem, eszopiclone) that act on GABA-A receptors. The difference matters for older adults because GABAergic hypnotics increase the risk of falls, hip fractures, cognitive impairment, and complex sleep behaviors such as sleepwalking or sleep-driving 1.

In the phase 3 trial by Herring et al. (N=254 in the elderly subgroup), suvorexant 30 mg (higher than the current approved maximum) improved subjective total sleep time by approximately 20 minutes over placebo at week 4 in adults aged 65 and older, with next-morning somnolence as the most common adverse event 1. The FDA subsequently approved a lower dose range (5 mg, 10 mg, 15 mg, 20 mg) to reduce residual sedation. A 2020 pooled analysis of suvorexant trials found that the number needed to treat (NNT) for clinically meaningful sleep improvement in older adults was 8, comparable to younger cohorts 2.

The 2023 AGS Beers Criteria update explicitly lists benzodiazepines and Z-drugs as potentially inappropriate in older adults due to fall risk and delirium, but does not include dual orexin receptor antagonists (DORAs) such as suvorexant 3. That omission is deliberate. It reflects the lower incidence of balance-disrupting side effects observed with orexin antagonism compared with GABAergic sedation.

Recommended Starting Dose and Titration for Adults 65+

The FDA prescribing information for suvorexant specifies 10 mg as the recommended starting dose for all adults, including those 65 and older 4. No age-specific dose reduction is required.

Titration follows a straightforward path. If 10 mg does not produce adequate sleep after at least one week, the dose may be increased to 15 mg or 20 mg. The 20 mg dose is the maximum for any adult patient. A 5 mg starting dose is available for patients who may be especially sensitive to CNS-depressant effects, including frail older adults or those taking other sedating medications.

Timing is critical. Patients should take suvorexant within 30 minutes of intended bedtime and only when they can remain in bed for at least 7 hours. Taking the medication too early or with fewer sleep-opportunity hours increases the likelihood of residual next-morning drowsiness, a concern amplified in older adults who may already experience slower reaction times.

The dose should be reassessed at every follow-up visit. A practical titration framework for clinicians managing geriatric insomnia with suvorexant:

• Week 1 to 2: Start at 10 mg (or 5 mg in frail patients). Assess subjective sleep latency and total sleep time.
• Week 3 to 4: If response is insufficient and side effects are absent, increase to 15 mg.
• Week 5 to 8: If 15 mg remains inadequate, increase to 20 mg. Reassess fall risk and daytime somnolence at this dose.
• Every 4 to 8 weeks thereafter: Evaluate ongoing need. Trial a dose reduction or discontinuation if insomnia triggers (pain, nocturia, medication changes) have resolved.

Pharmacokinetics in Older Adults: What Changes and What Stays the Same

Suvorexant is metabolized primarily by CYP3A4, with minor contribution from CYP2C19 4. Its plasma half-life averages 12 hours across age groups. In pharmacokinetic studies submitted to the FDA, suvorexant exposure (AUC) was approximately 25% higher in elderly subjects compared with younger adults, but this increase did not reach the threshold warranting a mandatory dose reduction 4.

Renal impairment does not meaningfully alter suvorexant clearance because the drug is eliminated primarily through hepatic metabolism and biliary excretion, not renal filtration. Patients with mild to moderate hepatic impairment also do not require dose adjustment, though suvorexant has not been studied in severe hepatic impairment and should be avoided in that population 4.

Body composition shifts in aging (increased fat-to-lean mass ratio) can extend the duration of action for lipophilic drugs. Suvorexant is highly protein-bound (more than 99%) and lipophilic, which means older adults may experience slightly prolonged sedative effects. This is why clinicians should counsel patients about next-morning drowsiness, especially during the first week of therapy or after a dose increase.

CYP3A4 Drug Interactions: A Priority in Polypharmacy

Polypharmacy is the norm, not the exception, in adults over 65. A 2019 CDC analysis found that 42% of U.S. Adults aged 65 and older take five or more prescription medications 5. Because suvorexant relies on CYP3A4 for metabolism, this enzyme's inhibitors and inducers directly affect drug exposure.

Moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, fluconazole, grapefruit juice) increase suvorexant AUC. The FDA label mandates a maximum dose of 10 mg when suvorexant is co-administered with moderate CYP3A4 inhibitors 4.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) are contraindicated with suvorexant. Ketoconazole 400 mg daily increased suvorexant AUC by approximately 179% in a dedicated interaction study 4.

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) substantially decrease suvorexant plasma levels and may render it ineffective. The prescribing information notes that co-use is not recommended.

Common geriatric medications that interact with CYP3A4 include calcium channel blockers for hypertension, macrolide antibiotics for respiratory infections, and azole antifungals for onychomycosis. Before prescribing suvorexant, a medication reconciliation focusing on CYP3A4 pathways is essential.

Fall Risk and Balance: How Suvorexant Compares to Benzodiazepines and Z-Drugs

Falls are the leading cause of injury-related death in Americans 65 and older, accounting for over 44,000 deaths annually according to the CDC 6. Sedative-hypnotics are a modifiable contributor to fall risk, and the choice of sleep medication matters.

A retrospective cohort study published in JAMA Internal Medicine found that Z-drug use in older adults was associated with a 2.55-fold increased risk of hip fracture compared with non-use 7. Benzodiazepines carry a similarly elevated fracture risk. Suvorexant's clinical trial data showed no statistically significant increase in falls compared with placebo in the elderly subgroup of the Herring et al. Trial 1.

A 2022 systematic review in the Journal of Clinical Sleep Medicine examined DORAs (suvorexant and lemborexant) in older populations and concluded that these agents "represent a meaningful advance over traditional hypnotics for elderly patients with insomnia, primarily because of a more favorable balance-related safety profile" 8.

Suvorexant is not risk-free. Any medication that promotes sleep can impair nighttime arousal. Older adults who get up frequently at night (for nocturia, for example) should use nightlights and clear walking paths. Suvorexant's sedative effect peaks 2 to 3 hours after ingestion, which means the highest fall risk window is during the first half of the night.

Cognitive Safety and Delirium Considerations

Anticholinergic burden is a major driver of delirium and cognitive decline in hospitalized and community-dwelling older adults. Benzodiazepines, while not strongly anticholinergic themselves, act on GABA-A receptors in ways that disrupt memory consolidation and increase delirium incidence 3.

Suvorexant has no anticholinergic activity. Its mechanism targets orexin neuropeptides, which regulate wakefulness without directly affecting acetylcholine, histamine, or GABA neurotransmission. This pharmacologic distinction is clinically relevant: a post hoc analysis of the Herring et al. Trial data found no significant difference in next-day cognitive performance (measured by the Digit Symbol Substitution Test) between suvorexant and placebo groups in participants aged 65 and older 9.

For patients with mild cognitive impairment or early-stage dementia, suvorexant may offer a specific advantage. A 2020 randomized trial (N=277) examining suvorexant in patients with Alzheimer's disease dementia and insomnia found that 10 mg nightly improved total sleep time by 28 minutes versus placebo (P=0.005) without worsening cognition or increasing behavioral disturbances over 4 weeks 10. The Alzheimer's Association subsequently cited this trial as evidence supporting DORAs for insomnia in dementia populations.

Dr. Andrew Krystal, a sleep medicine specialist at UCSF, stated in his review of orexin antagonists: "The dual orexin receptor antagonist class offers clinicians treating older adults a hypnotic mechanism that avoids the two greatest pharmacologic liabilities in geriatric sleep medicine: GABAergic sedation and anticholinergic burden" 8.

Deprescribing: When and How to Stop Suvorexant in Older Adults

Chronic hypnotic use in older adults often continues indefinitely, even when the original insomnia trigger has resolved. The Canadian Deprescribing Network recommends reassessing all sedative-hypnotics in adults over 65 at least every 3 months 11.

Suvorexant does not cause the same physical dependence seen with benzodiazepines, but abrupt discontinuation after nightly use can produce rebound insomnia for 1 to 2 nights. A gradual approach works best:

• If on 20 mg, reduce to 15 mg for 5 to 7 nights, then to 10 mg for 5 to 7 nights, then discontinue.
• If on 10 mg, patients can often stop directly, though alternating nights of use for one week before full cessation may smooth the transition.
• Pair deprescribing with cognitive behavioral therapy for insomnia (CBT-I), which the American College of Physicians (ACP) recommends as first-line treatment for chronic insomnia in all adults 12.

The ACP's 2016 clinical practice guideline states: "CBT-I should be the initial treatment for chronic insomnia disorder in adults. Pharmacologic therapy should be considered only when CBT-I alone is insufficient" 12. This recommendation applies with particular force to older adults, who face higher risk from any sedative medication.

Special Populations Within the Geriatric Group

Not all older adults are the same. A strong 68-year-old marathon runner metabolizes drugs differently than a frail 88-year-old with sarcopenia and three comorbidities.

Frail older adults (Clinical Frailty Scale 5+): Start at 5 mg. Monitor for excessive daytime sleepiness at 48 hours, because the 12-hour half-life means steady state is not reached until approximately day 3. Do not exceed 10 mg in frail patients unless the benefit clearly outweighs the sedation risk.

Patients on opioids: Suvorexant and opioid analgesics both cause CNS depression. If co-prescription is unavoidable, use the lowest effective dose of each. The FDA label carries a general warning about CNS-depressant combinations 4.

Patients with sleep apnea: Suvorexant has been studied in patients with mild to moderate obstructive sleep apnea (OSA) and did not worsen the apnea-hypopnea index (AHI) in a 4-week crossover study 13. This is an advantage over benzodiazepines, which can suppress respiratory drive. Patients with severe untreated OSA should still be evaluated and treated with CPAP or an oral appliance before adding any hypnotic.

Patients with hepatic impairment: Mild to moderate impairment requires no dose change. Severe hepatic impairment is a contraindication due to lack of safety data.

Monitoring and Follow-Up After Initiation

Clinicians should schedule a follow-up within 2 to 4 weeks of starting suvorexant in any patient aged 65 or older. Key assessment points at each visit:

1. Subjective sleep quality: Ask about sleep latency, nighttime awakenings, and total sleep time. A sleep diary kept for at least 5 of 7 nights provides more reliable data than single-visit recall.
2. Next-morning sedation: Use a simple question: "Do you feel alert enough to drive by 8 AM?" If the answer is no, reduce the dose or reassess timing.
3. Fall events or near-falls: Document any incidents. A single fall on suvorexant warrants reassessment of the risk-benefit ratio.
4. Medication changes: Any new CYP3A4 inhibitor added to the regimen may require a suvorexant dose reduction to 10 mg or discontinuation.
5. Ongoing insomnia triggers: Screen for untreated pain, nocturia, restless legs syndrome, depression, or poorly controlled sleep apnea, all of which are common in older adults and may be driving persistent insomnia independent of orexin signaling.

The Epworth Sleepiness Scale (ESS), while not specifically validated for monitoring DORA therapy, can serve as a standardized daytime sleepiness measure at baseline and follow-up visits. An ESS score increase of 3 or more points from baseline suggests medication-related over-sedation 14.